Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

Purpose of Review Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK inhibitors (ALKi): clinical activity, safety...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current oncology reports 2021-01, Vol.23 (1), p.10-10, Article 10
Hauptverfasser:	Tabbò, Fabrizio, Passiglia, Francesco, Novello, Silvia
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Clinical trials Disease control Lung cancer Lung Cancer (H Borghaei Medicine Medicine & Public Health Metastases Metastasis Non-small cell lung carcinoma Oncology Protein-tyrosine kinase Section Editor Small cell lung carcinoma Targeted cancer therapy Topical Collection on Lung Cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!